FDA extended the indication for Cianna Medical's Scout reflector, allowing the device to be used to mark soft tissue sites including lymph nodes.
News & Features
A new process for ozone sterilization could resolve earlier limitations with the gas and position it as a solution for complex and fragile products.
Boston Scientific recently disclosed that it is laying off 85 employees at a facility that came with the company's acquisition of Cosman Medical two years ago.
Some of medtech’s largest companies are working for approval in the TMVR space, which could one day rival or surpass TAVR.
Stryker's 3D-printed Tritanium cages outperformed PEEK cages in terms of bone in-growth and fixation in a pre-clinical study using sheep.
FDA has given approval for the Roche’s cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, a collection medium commonly used for Pap tests.
JenaValve has started an early feasibility study of the Pericardial TAVR technology for the minimally invasive treatment of patients with symptomatic, severe aortic stenosis, and symptomatic, severe aortic regurgitation.
Pentax acquired PlasmaBiotics to strengthen its hygiene portfolio and reduce cross-contamination risks associated with endoscopy devices.
Researchers found that SelectMDx, a test for prostate cancer, had a cost-savings of $1,694 per patient.
Mazor Robotic's revenue took a big hit in the second quarter due to lower pricing under its agreement with Medtronic, but the company expects the benefits of the agreement to win out over the drawbacks.
Valeritas Holdings has developed V-Go, a wearable insulin delivery device and presented data about the technology at the Metabolic & Endocrine Disease Summit in San Diego, CA.
DexCom CEO Kevin Sayer said the company's "fantastic quarter" demonstrates that continuous glucose monitoring (CGM) adoption is increasing significantly. But strong demand for the company's new G6 CGM has led to delays in processing and fulfilling orders.
The company said it needs $2 million to complete development of its Auracis wearable electrostimulation migraine technology and bring the device to the U.S. market.